The overview of pharmacoeconomic systematic reviews_Chinese Journal of Evidence-Based Medicine

Authors：

MI Xue ^1,2,3,4 , LI Jialian ^1,2,3 , CHEN Min ^1,2,3 , ZENG Linan ^1,2,3 , HUANG Zongyao ^1,2,3,5 , SONG Haoxin ^1,2,3,5 ,  ZHANG Lingli ^1,2,3

1. Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, 610041, P.R.China;
2. Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, 610041, P.R.China;
3. Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, 610041, P.R.China;
4. West China School of Medicine, Sichuan University, Chengdu, 610041, P.R.China;
5. West China School of Pharmacy, Sichuan University, Chengdu, 610041, P.R.China;

Corresponding author：

ZHANG Lingli, Email: zhanglingli@scu.edu.cn

Keywords：

Pharmacoeconomic; Systematic reviews; Overview of systematic reviews

DOI：

10.7507/1672-2531.201808144

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objectives To survey the systematic reviews of pharmacoeconomic evaluations.Methods Databases including The Cochrane Library, PubMed, EMbase (Ovid), NHS EED (Ovid), CENTRAL, Health Technology Assessment (HTA) Database, CNKI, WanFang Data, VIP and CBM were searched from inception to May 2018 to collect systematic reviews of pharmacoeconomic evaluations. Two reviewers independently screened literature and extracted data. Data statistics and frequency analysis were then conducted on the basic characteristics of included literatures, which involves the publication journal type and influencing factors (IF), disease type, quality assessment tool, etc. The amended AMSTAR scale was used to assess the methodological quality of pharm-SR.Results One hundred and forty-three systematic reviews were included in the overview. The UK had a large number of publications (39.8%), which were mostly published in the Health Technology Assessment and Pharmacoeconomics. Among the included literatures, most were evaluated tumor related pharmacoeconomics systematic reviews (20.8%). They searched on average 7.42±4.00 databases. The British Medical Journal checklist (20.15%) and the Drummond checklist (19.40) were the main tools for quality evaluation. The methodological qualities of these studies were not high.Conclusions The evidence shows that the number of systematic reviews of pharmacoeconomic is increasing and research methodology is gradually unifying. However, the quality is still required to be further improved.

Citation： MI Xue, LI Jialian, CHEN Min, ZENG Linan, HUANG Zongyao, SONG Haoxin, ZHANG Lingli. The overview of pharmacoeconomic systematic reviews. Chinese Journal of Evidence-Based Medicine, 2019, 19(2): 212-217. doi: 10.7507/1672-2531.201808144 Copy

1.	Oxman AD, Schunemann HJ, Fretheim A, et al. Improving the use of research evidence in guideline development: 8. Synthesis and presentation of evidence. Health Res Policy Syst, 2006, 4: 20.
2.	Benedicto AS, Ruiz VG. Inappropriate use of health resources and the trivialisation of medicine. Atencion Primaria, 2013, 45(5): 274-277.
3.	Kanchanachitra C, Lindelow M, Johnston T, et al. Health in Southeast Asia 5 Human resources for health in southeast Asia: shortages, distributional challenges, and international trade in health services. Lancet, 2011, 377(9767): 769-781.
4.	Sun J, Luo H. Evaluation on equality and efficiency of health resources allocation and health services utilization in China. Int J Equity Health, 2017, 16(1): 127.
5.	Yagudina RI, Kulikov AU, Serpik VG, et al. Concept of combining cost-effectiveness analysis and budget impact analysis in health care decision-making. Value Health Reg Issues, 2017, 13: 61.
6.	Cazarim MDS, Reis R, Wu O, et al. Development and validation of a pharmacoeconomic tool for decision making in the implementation of pharmaceutical care for hypertensive patients in the Brazilian public health system (SUS). Procedia Computer Science, 2017, 121: 376-383.
7.	Simoens DS. Use of economic evaluation in decision making. Drugs, 2010, 70(15): 1917-1926.
8.	Mazumder D, Kapoor A, Gwatkin N, et al. Benchmarking health technology assessment (HTA) agencies for setting standards on pharmacoeconomic, pricing, evidence, and general submission requirements: development of a multidimensional rating scale. Value Health, 2015, 18(7): A854.
9.	Lavis JN, Permanand G, Oxman AD, et al. SUPPORT tools for evidence-informed health policymaking (stp) 13: preparing and using policy briefs to support evidence-informed policymaking. Health Res Policy Syst, 2009, 7(S1): S3.
10.	Phelps CE, Lakdawalla DN, Basu A, et al. Approaches to aggregation and decision making-a health economics approach: an ISPOR Special Task Force report. Value Health, 2018, 21(2): 146-154.
11.	Shiroiwa T, Fukuda T, Ikeda S, et al. New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations. Health Policy, 2017, : S0168851017301653.
12.	Schuller Y, Hollak CEM, Biegstraaten M. The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic review. Orphanet J Rare Dis, 2015, 10(1): 92.
13.	Drummond MF. Economic evaluation of pharmaceuticals: science or marketing. Pharmacoeconomics, 1993, 3(1): 86-86.
14.	李迅, 曹卉娟(译). 系统综述和荟萃分析优先报告的条目: PRISMA声明. 中西医结合学报, 2009, 7(9): 889-896.
15.	Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ, 1996, 313(7052): 275-283.
16.	Listersharp D, Mcdonaugh M, Khan K, et al. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer. Health Technology Assessment, 2000, 4(17): 1-113.
17.	孙鑫, 杨焕, 王莉, 等. 中国治疗慢性乙型肝炎的成本-效果的系统评价. 中国循证医学杂志, 2005, 5(11): 833-845.
18.	熊鹰. 三种药物治疗良性前列腺增生症的卫生技术评估. 四川: 四川大学, 2005.
19.	熊俊, 陈日新. 系统评价/Meta分析方法学质量的评价工具AMSTAR. 中国循证医学杂志, 2011, 11(9): 1084-1089.
20.	Doran CM. Critique of an economic evaluation using the drummond checklist. Applied Health Economics Health Policy, 2010, 8(6): 357.
21.	Delaney A, Bagshaw SM, Ferland A, et al. A systematic evaluation of the quality of meta-analyses in the critical care literature. Critical Care, 2005, 9(5): R575-R582.

1. Oxman AD, Schunemann HJ, Fretheim A, et al. Improving the use of research evidence in guideline development: 8. Synthesis and presentation of evidence. Health Res Policy Syst, 2006, 4: 20.
2. Benedicto AS, Ruiz VG. Inappropriate use of health resources and the trivialisation of medicine. Atencion Primaria, 2013, 45(5): 274-277.
3. Kanchanachitra C, Lindelow M, Johnston T, et al. Health in Southeast Asia 5 Human resources for health in southeast Asia: shortages, distributional challenges, and international trade in health services. Lancet, 2011, 377(9767): 769-781.
4. Sun J, Luo H. Evaluation on equality and efficiency of health resources allocation and health services utilization in China. Int J Equity Health, 2017, 16(1): 127.
5. Yagudina RI, Kulikov AU, Serpik VG, et al. Concept of combining cost-effectiveness analysis and budget impact analysis in health care decision-making. Value Health Reg Issues, 2017, 13: 61.
6. Cazarim MDS, Reis R, Wu O, et al. Development and validation of a pharmacoeconomic tool for decision making in the implementation of pharmaceutical care for hypertensive patients in the Brazilian public health system (SUS). Procedia Computer Science, 2017, 121: 376-383.
7. Simoens DS. Use of economic evaluation in decision making. Drugs, 2010, 70(15): 1917-1926.
8. Mazumder D, Kapoor A, Gwatkin N, et al. Benchmarking health technology assessment (HTA) agencies for setting standards on pharmacoeconomic, pricing, evidence, and general submission requirements: development of a multidimensional rating scale. Value Health, 2015, 18(7): A854.
9. Lavis JN, Permanand G, Oxman AD, et al. SUPPORT tools for evidence-informed health policymaking (stp) 13: preparing and using policy briefs to support evidence-informed policymaking. Health Res Policy Syst, 2009, 7(S1): S3.
10. Phelps CE, Lakdawalla DN, Basu A, et al. Approaches to aggregation and decision making-a health economics approach: an ISPOR Special Task Force report. Value Health, 2018, 21(2): 146-154.
11. Shiroiwa T, Fukuda T, Ikeda S, et al. New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations. Health Policy, 2017, : S0168851017301653.
12. Schuller Y, Hollak CEM, Biegstraaten M. The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic review. Orphanet J Rare Dis, 2015, 10(1): 92.
13. Drummond MF. Economic evaluation of pharmaceuticals: science or marketing. Pharmacoeconomics, 1993, 3(1): 86-86.
14. 李迅, 曹卉娟(译). 系统综述和荟萃分析优先报告的条目: PRISMA声明. 中西医结合学报, 2009, 7(9): 889-896.
15. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ, 1996, 313(7052): 275-283.
16. Listersharp D, Mcdonaugh M, Khan K, et al. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer. Health Technology Assessment, 2000, 4(17): 1-113.
17. 孙鑫, 杨焕, 王莉, 等. 中国治疗慢性乙型肝炎的成本-效果的系统评价. 中国循证医学杂志, 2005, 5(11): 833-845.
18. 熊鹰. 三种药物治疗良性前列腺增生症的卫生技术评估. 四川: 四川大学, 2005.
19. 熊俊, 陈日新. 系统评价/Meta分析方法学质量的评价工具AMSTAR. 中国循证医学杂志, 2011, 11(9): 1084-1089.
20. Doran CM. Critique of an economic evaluation using the drummond checklist. Applied Health Economics Health Policy, 2010, 8(6): 357.
21. Delaney A, Bagshaw SM, Ferland A, et al. A systematic evaluation of the quality of meta-analyses in the critical care literature. Critical Care, 2005, 9(5): R575-R582.

Chinese Journal of Evidence-Based Medicine

The overview of pharmacoeconomic systematic reviews

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content